Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
2.110
-0.060 (-2.76%)
At close: May 9, 2025, 4:00 PM
2.120
+0.010 (0.47%)
After-hours: May 9, 2025, 5:52 PM EDT
Heron Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Heron Therapeutics stock have an average target of 5.50, with a low estimate of 4.00 and a high estimate of 7.00. The average target predicts an increase of 160.66% from the current stock price of 2.11.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Heron Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +89.57% | Apr 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +89.57% | Feb 28, 2025 |
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +89.57% | Dec 4, 2024 |
| Needham | Needham | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +89.57% | Nov 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +136.97% | Sep 25, 2024 |
Financial Forecast
Revenue This Year
160.41M
from 144.29M
Increased by 11.18%
Revenue Next Year
181.51M
from 160.41M
Increased by 13.15%
EPS This Year
-0.04
from -0.09
EPS Next Year
0.10
from -0.04
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 167.3M | 186.9M | 211.2M | ||
| Avg | 160.4M | 181.5M | 204.7M | ||
| Low | 151.9M | 174.3M | 196.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.9% | 16.5% | 16.3% | ||
| Avg | 11.2% | 13.2% | 12.8% | ||
| Low | 5.3% | 8.7% | 8.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 0.16 | 0.22 | ||
| Avg | -0.04 | 0.10 | 0.20 | ||
| Low | -0.06 | 0.05 | 0.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 116.2% | ||
| Avg | - | - | 95.0% | ||
| Low | - | - | 72.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.